Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Matteo LambertiniChristine CampbellRichard D GelberGiuseppe VialeAnn McCulloughFlorentine HilbersLarissa A KordeOlena WernerSaranya ChumsriChristian JackischAntonio C WolffInes Vaz-LuisArlindo R FerreiraAleix PratAlvaro Moreno-AspitiaMartine PiccartSherene LoiEvandro de Azambuja

Published in: Breast cancer research and treatment (2019)

HER2-positive early breast cancer is characterized by the presence of two diseases with distinct natural history based on HR status requiring the development of different follow-up strategies and future de-escalation and escalation clinical trials.

Keyphrases

early breast cancer
clinical trial
open label
big data
current status
double blind
phase ii
randomized controlled trial
study protocol